OncoDEEP

OncoDEEP is a service to help personalized oncological diagnostics which consists in a panel of 65 genes selected for their clinical relevance in cancer. We employ ultrasequencing technology.

This genetic test and the subsequent bioinformatics analysis allow to identify the biomarkers of each patient in order to predict the prognosis and tumor evolution, and also to offer more appropriate and personalized treatment options.

Along with the ultrasequencing panel, complementary and specific tests (IHC, FISH analysis of translocations, etc.) are carried out to complete the characterization of the tumor of the patient. These tests are cancer type specific and look at special DNA modifications (translocations’ effect, microsatellite, methylation, …) as well as presence and/or activation of protein effectors with IHCs and Phospho-IHCs obtaining information about sensitivity or resistance to different types of chemotherapies or other drugs and allowing the better treatment customization.

The OncoDEEP panel has been selected for its clinical and research applications:

  • It helps to identify each tumor unique characteristics to treat it accurately.
  • It increases treatment options for cancer patients.
  • It helps today’s treatments be more cost-effective and offers targeted therapies for patients.
  • It offers treatment possibilities to patients with unknown tumor origin.
  • It helps cut the costs and time of new drugs studies.
  • It helps obtain results adapted to the research project’s requirements.

The oncological report not only offers the ultrasequencing results, but interprets them by a
bioinformatics and a clinical analysis.

 

The end result of this report contains the following contents:


  • Mutations present in the tumor.
  • Association of the mutations with tumor development and progression.
  • Association of the mutations with specific treatments.
  • Association of the mutations with clinical trials.
  • Association of the IHC, FISH,… results with sensivility or resistance to different types of chemotherapies or other drugs.

OncoDEEP has been designed to analyze all types of tumor samples.

The delivery time of this clinical service is 7 days (after receiving the sample and verifying its quality).

The results will be periodically discussed with a specialist team in order to acquire and improve knowledge about genomic tests.

The genomic analysis is done by the OncoDNA (Belgium).

  1. The oncologist will be notified by email about when the report results will be ready, which can be downloaded from a document management platform.
  2. If the sample does not share any of the genes on the panel, there are other strategies which must be assessed by our team of specialists.

If you are a specialist and you wish to receive more detailed information about OncoDEEP, please contact us by filling out this form or call on +34 961 829 423.

 The efficacy of targeted next-generation sequencing for detection of clinically actionable mutations in

cancer. Wen YY, Fang E, Li Y, Carmack CE, Li MM; Baylor College of Medicine, Houston, TX.

J Clin Oncol 30, 2012 (suppl; abstr 10598).